OpSens Inc. announced that it has received Health Canada approval to commence the first in-man study with its SavvyWire, a guidewire developed specifically for transcatheter aortic valve replacement ("TAVR"). The SavvyWire is the first guidewire intended to both deliver the aortic valve prosthesis while allowing continuous hemodynamic pressure measurement during the procedure. Health Canada's approval allows OpSens to commence the 20-patients study shortly at two world-renowned structural cardiology institutions that contributed to the development of the SavvyWire. Dr. Josep Rodés-Cabau at The Quebec Heart and Lung Institute Research Centre ("IUCPQ") and Dr. Réda Ibrahim at The Montreal Heart Institute ("MHI") will be the primary investigators. Aortic valve stenosis occurs when the heart's aortic valve narrows, which prevents the valve from opening fully, restricting blood flow from the heart into the main artery (aorta) and onward to the rest of the body. Initially, the TAVR procedure was only indicated for inoperable patients and then for high-risk surgical patients. Clinical programs like PARTNER or COREVALVE, have since shown better or equivalent clinical outcomes in intermediate and low-risk patients. The TAVR procedure is now evolving quickly with a minimalist approach that allows the procedure to be faster and the patients to be discharged earlier, sometimes on the same day.